Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Surgical Management Clear all

Conditions: Parkinson's Disease
Interventions: Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus; Genetic
Lead sponsor: Neurologix, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 7
States / cities: Stanford, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Labor
Interventions: Laboraide TM dental support device; Device
Lead sponsor: Angela Bianco; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Pelvic Floor Disorders
Interventions: Standard of Care, Active Recovery; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Urinary Incontinence, Geriatric Syndrome
Interventions: Hip Muscle Exercise; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 65 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Melanoma, Skin Cancer, Cancer
Interventions: Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: High Risk Cutaneous Squamous Cell Carcinoma
Interventions: elective lymph node dissection; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 154
States / cities: Birmingham, Alabama • Duarte, California • Dublin, California + 127 more

Conditions: Metastatic Melanoma
Interventions: Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2; Procedure · Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Colorectal Carcinoma, Lynch Syndrome
Interventions: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Single-ventricle
Interventions: Spironolactone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 6 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ductal Adenocarcinoma of Pancreas, Adenocarcinoma of Ampulla
Interventions: Gemcitabine and nanoparticle albumin bound paclitaxel, 5-fluorouracil and irinotecan, Preoperative chemoradiation, Definitive resection; Drug · Radiation · Procedure
Lead sponsor: Essentia Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Carpometacarpal Osteoarthritis
Interventions: Acetaminophen, Placebo: Multivitamin; Drug · Other
Lead sponsor: Indiana Hand to Shoulder Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Arthroplasty, Replacement, Hip
Interventions: CHG 2% w/v and IPA 70% v/v, Iodophor 0.7% and IPA 74% w/w; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy; Procedure · Other · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 75 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2075
U.S. locations: 164
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more

Conditions: Head and Neck Cancer
Interventions: capecitabine, Surgery, chemotherapy and/or radiotherapy; Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Bunionectomy, Orthopedic Surgery
Interventions: Lornoxicam 8 mg, Lornoxicam 16 mg, Ketorolac 30 mg, Placebo; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 80 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma
Interventions: Indocyanine green solution administered at 2.0mg/kg., Stryker SPY-PHI Imaging Device; Drug · Device
Lead sponsor: Kurt Weiss; Other
Eligibility: 18 Years to 100 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Melatonin, Placebo (for Melatonin); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 280
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more

Conditions: Surgery, Anesthesia
Interventions: Desflurane, Administration of Sevoflurane; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anesthesia; Adverse Effect
Interventions: Routine opioid management, PMD-200 Nol-guided opioid administration; Drug · Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration; Drug · Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Search by objective public record fields.

Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease

Dental Support Device in the Second Stage of Labor

Postoperative Active Recovery

The Impact of Hip Exercises on Pelvic Floor Muscle Strength and Function in Older Women With Urinary Incontinence

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC)

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Fibrosis and the Fontan

Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Effect of Perioperative Acetaminophen Dosing on Patients Undergoing Surgical Treatment of Basilar Thumb Arthritis

Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy

Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease

Fluorescent Intra-operative Tumor Margin Examination

Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

A Comparison of Desflurane vs. Sevoflurane and the Time to Awakening and the Incidence and Severity of Cough

Postoperative Consequences of Intraoperative NOL Titration

Q702 for the Treatment of Patients With Hematologic Malignancies